A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Wei Zhang, Bachelor
The Second Affiliated Hospital of Harbin Medical University
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Beijing Anzhen Hospital Capital Medical University
Beijing, Beijing Municipality, China
- the 2nd Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
- Linfen Central Hospital
Linfen, Shanxi, China
- Teda International Cardiovascular Hospital
Tianjin, Tianjin Municipality, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 20 Jan 2025
- Primary completion
- 18 Jul 2025
- Completion
- 18 Jul 2025
- Last update posted
- 12 Jan 2026
- Registered enrollment
- 38
- Registry id
- NCT07091929
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.